A Common Data Model for Oral Anticoagulants-related Risk of Spontaneous Intracranial Hemorrhage (Preprint)
Open Access
- 1 May 2024
- journal article
- Published by JMIR Publications Inc. in Interactive Journal of Medical Research
Abstract
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Spontaneous intracranial hemorrhage (sICH) is a major complication associated with oral anticoagulation which results in a high mortality rate, and the incidence of anticoagulant-induced sICH has increased markedly, so it is necessary to investigate the risk of anticoagulation-related sICH in a real-world setting. Objective: We aimed to investigate the incidence and risk factors of oral anticoagulant-related sICH using a common data model (CDM), and to determine whether a clinical study using the CDM would be comparable to conventional studies. Methods: After converting the various clinical codes of 12,821 patients taking oral anticoagulants, such as warfarin and non-vitamin K antagonist oral anticoagulants (NOACs), into the Observational Medical Outcomes Partnership (OMOP) CDM format, we analyzed the incidence and risk factors of sICH. Results: sICH occurred in 0.5% of 5,626 patients with warfarin and 0.2% of 7,195 patients with NOAC. The mean duration of warfarin and NOACs before sICH occurrence was 251.4 ± 373.6 and 124.2 ± 135.7 days, respectively. Multivariable analysis showed significant risk factors of the sICH, such as warfarin over NOACs; hypertension; diabetes mellitus; brain tumors; and decreased duration of oral anticoagulation. Conclusions: NOAC demonstrated a lower risk of sICH than warfarin in a real-world setting using OMOP CDM confined to a single institution. Clinical studies using a CDM for the multicenter datasets may provide more reliable information about the risk of sICH.Keywords
This publication has 37 references indexed in Scilit:
- Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology AssessmentPharmacoEconomics, 2020
- Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0Neurocritical Care, 2017
- Coagulation Testing in Intracerebral Hemorrhage Related to Non-vitamin K Antagonist Oral AnticoagulantsNeurocritical Care, 2017
- Intracranial hemorrhage with target specific oral anticoagulants in patients with atrial fibrillation: An updated meta-analysis of randomized controlled trialsInternational Journal of Cardiology, 2016
- Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysisJournal of Neurology, 2014
- Intracerebral hemorrhage during anticoagulation with vitamin K antagonists: a consecutive observational studyJournal of Neurology, 2013
- Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)American Heart Journal, 2010
- Rivaroxaban—Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: Rationale and Design of the ROCKET AF studyAmerican Heart Journal, 2010
- Apixaban for Reduction In Stroke and Other ThromboemboLic Events in Atrial Fibrillation (ARISTOTLE) trial: Design and rationaleAmerican Heart Journal, 2010
- Rationale and design of RE-LY: Randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatranAmerican Heart Journal, 2009